BioNTech's Re-Rating Race: Analysts Split as Oncology Pipeline Overshadows Shrinking COVID Franchise

Morgan Stanley lifts BioNTech target to $145, citing oncology catalysts, while COVID revenue shrinks and analysts remain split on valuation.

The most telling signal in BioNTech's recent rally isn't the share price — it's the speed with which one Wall Street house has torn up its own spreadsheet. Morgan Stanley's Terence Flynn lifted his price target from $93 to $145 on Wednesday while upgrading the stock from Equalweight to Overweight, a move that effectively concedes the bank's previous model had it wrong. The question now hanging over the Mainz-based biotech is whether that kind of conviction is prescient or premature.

A House Divided on Valuation

The analyst community has rarely looked more fractured on a single name. Morgan Stanley now marks the bull case at $145, while Citi, Evercore ISI and Berenberg trimmed their targets to $125, $130 and $132 respectively in early August — though all three retained Buy or Outperform ratings. J.P. Morgan has held a "Hold" since August 6, with the consensus sitting near $121 at that point. Canaccord Genuity moved in Morgan Stanley's direction earlier, lifting its target to $142 on August 5 with the same rationale: three expected clinical readouts by year-end and the impending CEO transition.

What makes the upgrades notable is that they arrive despite deteriorating COVID-era guidance. Canaccord explicitly flagged the "weaker COVID guidance" yet still chose to lean into the oncology narrative — a sign of just how thoroughly the valuation logic has decoupled from vaccine revenue.

The Numbers Tell a Two-Sided Story

The revenue base underneath all this optimism remains strikingly thin. BioNTech generated just €105.6 million in second-quarter sales, down from €260.8 million in the same period a year earlier. The company cut its full-year forecast to €1.6–1.9 billion roughly three weeks ago — and the stock has climbed 22.7% since. That divergence between weakening fundamentals and a rising share price captures the entire debate: investors are pricing tomorrow's pipeline, not today's income statement.

That pipeline is genuinely substantial. Six registration-enabling studies were launched in the second quarter, five for the cancer drug Pumitamig and one for the antibody-drug conjugate Elfetabart Drozuntecan. Data presented at the ASCO congress showed consistent efficacy for Pumitamig in non-small cell lung cancer across varying PD-L1 expression levels — the third global dataset to demonstrate that pattern. With €16.6 billion in cash at quarter-end, BioNTech has ample runway to fund these trials without capital constraints.

A New Chapter at the Top

The leadership transition adds another layer to the story. Guido Oelkers has been named to succeed Prof. Ugur Sahin as CEO no later than February 1, 2027, and the stock has gained 23.1% since that announcement roughly a month ago. The market appears to be rewarding a shift toward more professional commercialization management precisely as the pipeline heads into several late-stage readouts.

The combination of a leadership change and concrete clinical catalysts before year-end is what separates this rally from mere momentum trading. Even the reduced 2026 revenue guidance failed to dent the stock — it has risen 22.3% since that update, reinforcing the view that the shrinking COVID business, now a footnote at €105.6 million in quarterly sales, has been fully priced in.

Cautionary Signals Amid the Enthusiasm

Not every indicator points the same direction. Sierk Poetting, the company's Chief Operating Officer, sold shares worth roughly $5.5 million in August. Insider selling isn't necessarily a red flag, but it does temper some of the analyst enthusiasm. Institutional positioning is similarly mixed: FMR LLC increased its stake by 32.6% in the second quarter, while Flossbach von Storch cut its holding by 39.5%.

The stock trades at €96.95, about 8.4% below its 52-week high of €105.80 but 42% above its annual low. That range mirrors the uncertainty among analysts: the pipeline opportunity appears to outweigh near-term revenue concerns, but the wide spread in price targets suggests this bet is far from settled.

The Seoul Catalyst and Beyond

BioNTech announced on August 20 that it will present new data at the WCLC lung cancer conference in Seoul from September 12–15, 2026, combining Pumitamig — developed with Bristol Myers Squibb — and Elfetabart Drozuntecan, created with Duality Biologics of Suzhou. The pairing is notable because it combines two independently developed candidates rather than layering onto existing chemotherapy.

Less prominent but strategically significant is the ongoing study of BNT168, an RNA-based HIV vaccine candidate, which received an update on August 20. The mRNA platform is clearly being positioned as a general-purpose technology for difficult infectious diseases, not just oncology and COVID.

The breadth of the oncology pipeline — two distinct drug classes backed by partnerships with Bristol Myers Squibb and Duality Biologics — argues for a company that isn't dependent on a single molecule. The leadership change should reinforce that transformation by bringing commercial experience into an organization historically driven by science. Clinical trials can still fail, and COVID revenues will keep shrinking, but for now the coming data readouts carry more weight than the lingering uncertainties.